Science Translational Medicine Publishes Article Outlining Development of a Fibrin-Targeted Theranostic for Gastric Cancer

In the publication, the authors describe a theranostic approach for targeting fibrin deposition in the tumor extracellular matrix first with a copper-64 labeled, fibrin-specific positron emission tomography (PET) imaging probe and then with a yttrium-90 labeled fibrin-specific therapeutic to treat gastric cancer.

Lumina Pharmaceuticals Awarded $2 million SBIR Phase II Fast Track NIH Grant to Support the Development of Novel Therapeutics to Solid Tumor Cancer

The Fast Track award from NCI represents another important milestone for Lumina as we continue to advance our platform of targeted molecular probes for medical imaging and radioligand therapy,